Vyxeos (daunorubicin and cytarabine)

pCPA File Number: 21588
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Sponsor/Manufacturer:
Jazz Pharmaceuticals Canada Inc.
CADTH Project Number:
PC0237-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable